Phase 2 N=110 Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Dilated Cardiomyopathy
Primary: Heart Failure Mortality — 8; 19 participants — p=0.01
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=510 Prevention of Pegfilgrastim-Induced Bone Pain (PIBP)
Musculoskeletal Complications · Pain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Area Under Curve (AUC) of Average Pain From Diary vs. Day (1-5), Calculated by the Trapezoidal Rule. — 6.04; 7.71 (Pain Scale Score)*Days — p=0.037
Phase 2 N=68 Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery
Acute Pain
Primary: Responders on Pain Intensity(PI) and Pain Relief (PR) Composite Endpoint — 1; 1 responders
Phase 2 N=64 Bevacizumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer
Primary Peritoneal Cavity Cancer · Recurrent Ovarian Epithelial Cancer · Stage IV Ovarian Epithelial Cancer
Primary: Progression-free Survival at 6 Months — 40.3 percentage of participants
Phase 2 N=14 Dose-Escalation Safety Study of HPN-100 to Treat Urea Cycle Disorders
Urea Cycle Disorders
Primary: Venous Ammonia Levels at the Peak and Mean TNUAC Time-normalized Area Under the Curve) — 79.1; 56.3; 38.4; 26.5 μmol/L
Phase 3 N=487 Long-Term, Open-Label Study Of CP-690,550 For Treatment Of Rheumatoid Arthritis In Japan
Rheumatoid Arthritis
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs) — 371; 105; 476; 111 Particiants
N/A N=107 Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
Influenza
Primary: Determination of Immune Response to Vaccination. — 45 participants
N/A N=1,685 Study Evaluating The Use Of Etanercept In Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
Primary: Percentage of Participants Achieving Partial Remission at Week 26 — 19.0 percentage of participants
Phase 3 N=94 Treatment Strategy to Prevent Mood Disorders Following Traumatic Brain Injury
Traumatic Brain Injury
Primary: Time to Onset of Diagnostic and Statistical Manual (DSM) IV Defined Mood and Anxiety Disorders Associated With Traumatic Brain Injury (TBI) — 21.4264; 15.7833 weeks…
Phase 4 N=140 A Study for Patients With Neurogenic Orthostatic Hypotension
Hypotension, Orthostatic
Primary: Post-treatment Score For Item 1 of The Orthostatic Hypotension Symptom Assessment (OHSA) Scale — 4.1; 5.2 scores on a scale — p=<0.001
N/A N=71 Electrode-Based Sensor for Non-Invasive Fetal Heart Rate Monitoring With Improved Reliability
Laboring Women With Ultrasound and FSE Monitoring
Primary: Fetal Heart Rate Interpretability — 83.4; 62.4 percentage of time the signals are inter
Phase 3 N=133 Efficacy Study of Ambrisentan in Chinese Patients With Pulmonary Arterial Hypertension (PAH)
Vascular Disease
Primary: Change From Baseline in 6-minutes Walk Test (6MWT) at Week 12 — 53.59 Meters — p=<0.001
Phase 3 N=982 An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
Bacterial Conjunctivitis
Primary: Clinical Cure Rate — 85.4; 81.4 percentage of participants
Phase 2 N=5 Combined Kidney and Bone Marrow Transplantation to Prevent Kidney Transplant Rejection
Kidney Transplantation · Kidney Failure, Chronic
Primary: Number of Participants Successfully Withdrawn Off of Immunosuppressant Medication for 104 Weeks — 3 participants
Phase 4 N=64 Barbed Suture vs Smooth Suture for Vaginal Cuff Closure
Closure of Vaginal Cuff at Laparoscopic Hysterectomy
Primary: Vaginal Cuff Closure Time — 10.4; 9.6 minutes